Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in relapsed/refractory classical Hodgkin's lymphoma
2012-004246-15Phase 2Completed
- Sponsor
- LYSARC
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in Hodgkin lymphoma (HL), sponsored by LYSARC. Started May 2013; status: completed.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2012-004246-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004246-15.